ABBVAbbVie

Healthcare

$276.40+27% 1Y

$276.40

$197.3852 weeks$276.40

Latest close: a new 52-week highOct 9, 2026what changed →

Is the price fair?

Watch

A demanding price: at the top of its own P/E range and rich vs its sector.

2 to watch, 1 neutral

What the price assumes~+6% a year

Priced for ~6% a year FCF growth. Roughly in line with its three-year revenue growth of 5% a year.

Vs its own P/E rangedearer than 88% of its own historyderived

Expensive vs its own history: P/E 78.1 vs a 20.5 median over 41 quarters (+280% vs median).

Vs sector (EV/EBIT)26.5×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 7% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What ABBV's price assumes

AbbVie trades at 78.1× earnings against 26.2× for the median Drug Manufacturers - General name, more expensive than its own group.

78.1

Trailing P/E · Drug Manufacturers - General median 26.2 · 2.98× the median: the market pays up for this one

Price / sales: 5.94
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 4.8%
Free cash flow yield · Drug Manufacturers - General median 5.7%
Growth the price implies: +6.3%
Growth the price implies · The price pays for +6.3% free cash flow growth a year for a decade; the business has delivered −9.8% a year over the last three.